Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine

被引:71
作者
Garg, MB [1 ]
Ackland, SP [1 ]
机构
[1] Newcastle Mater Misericordiae Hosp, Dept Med Oncol, Waratah, NSW 2310, Australia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2000年 / 748卷 / 02期
关键词
docetaxel;
D O I
10.1016/S0378-4347(00)00356-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Several methods for quantification of docetaxel have been described mainly using HPLC. We have developed a new isocratic HPLC method that is as sensitive and simpler than previous methods, and applicable to use in clinical pharmacokinetic analysis. Plasma samples are spiked with paclitaxel as internal standard and extracted manually on activated cyanopropyl end-capped solid-phase extraction columns followed by isocratic reversed-phase HPLC and UV detection at 227 nm. Using this system, the retention times for docetaxel and paclitaxel are 8.5 min and 10.5 min, respectively, with good resolution and without any interference from endogenous plasma constituents or docetaxel metabolites at these retention times. The total run time needed is only 13 min. The lower limit of quantification is 5 ng/ml using 1 ml of plasma. The validated quantitation range of the method is 5-1000 ng/ml with RSDs less than or equal to 10%, but plasma concentrations up to 5000 ng/ml can be accurately measured using smaller aliquots. This method is also suitable for the determination of docetaxel in urine samples under the same conditions. The method has been used to assess the pharmacokinetics of docetaxel during a phase I/II study of docetaxel in combination with epirubicin and cyclophosphamide in patients with advanced cancer. (C) 2000 Elsevier Science BN. All rights reserved.
引用
收藏
页码:383 / 388
页数:6
相关论文
共 15 条
[1]  
ARDIET CJ, 1998, P AN M AM SOC CLIN, V17, P905
[2]  
BISSETT D, 1993, CANCER RES, V53, P523
[3]   PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR 6-HOUR INTRAVENOUS-INFUSION [J].
BURRIS, H ;
IRVIN, R ;
KUHN, J ;
KALTER, S ;
SMITH, L ;
SHAFFER, D ;
FIELDS, S ;
WEISS, G ;
ECKARDT, J ;
RODRIGUEZ, G ;
RINALDI, D ;
WALL, J ;
COOK, G ;
SMITH, S ;
VREELAND, F ;
BAYSSAS, M ;
LEBAIL, N ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :950-958
[4]   DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [J].
CHEVALLIER, B ;
FUMOLEAU, P ;
KERBRAT, P ;
DIERAS, V ;
ROCHE, H ;
KRAKOWSKI, I ;
AZLI, N ;
BAYSSAS, M ;
LENTZ, MA ;
VANGLABBEKE, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :314-322
[5]   Clinical pharmacokinetics of docetaxel [J].
Clarke, SJ ;
Rivory, LP .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :99-114
[6]   A HIGHLY EFFICIENT, PRACTICAL APPROACH TO NATURAL TAXOL [J].
DENIS, JN ;
GREENE, AE ;
GUENARD, D ;
GUERITTEVOEGELEIN, F ;
MANGATAL, L ;
POTIER, P .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (17) :5917-5919
[7]  
EXTRA JM, 1993, CANCER RES, V53, P1037
[8]   RELATIONSHIPS BETWEEN THE STRUCTURE OF TAXOL ANALOGS AND THEIR ANTIMITOTIC ACTIVITY [J].
GUERITTEVOEGELEIN, F ;
GUENARD, D ;
LAVELLE, F ;
LEGOFF, MT ;
MANGATAL, L ;
POTIER, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (03) :992-998
[9]   TAXANES - A NEW CLASS OF ANTITUMOR AGENTS [J].
HUIZING, MT ;
MISSER, VHS ;
PIETERS, RC ;
HUININK, WWT ;
VEENHOF, CHN ;
VERMORKEN, JB ;
PINEDO, HM ;
BEIJNEN, JH .
CANCER INVESTIGATION, 1995, 13 (04) :381-404
[10]   APPLICATION OF THE VICINAL OXYAMINATION REACTION WITH ASYMMETRIC INDUCTION TO THE HEMISYNTHESIS OF TAXOL AND ANALOGS [J].
MANGATAL, L ;
ADELINE, MT ;
GUENARD, D ;
GUERITTEVOEGELEIN, F ;
POTIER, P .
TETRAHEDRON, 1989, 45 (13) :4177-4190